GENinCode UK Ltd. (GB:GENI) has released an update.
GENinCode PLC has reported a robust 51% increase in year-on-year revenues, reaching £2.2m for FY23, with significant growth in the UK and European markets and an expansion into the US market following regulatory approvals. The company has also secured various commercial agreements and expects further revenue growth from US operations and existing markets. GENinCode’s predictive genetic tests for cardiovascular disease and ovarian cancer are gaining traction, with the company focusing on commercial expansion and FDA regulatory processes to boost US sales.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
